Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, et al.
Diabetologia (2022) Vol. 65, Iss. 8, pp. 1251-1261
Open Access | Times Cited: 184

Showing 1-25 of 184 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1158
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 680
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Rexiati Ruze, Tiantong Liu, Xi Zou, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 326
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 321
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Jingyue Wang, Quanwei Wang, Xinyu Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 125
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda, Jinal Ajabiya, Divya Teli, et al.
Molecules (2022) Vol. 27, Iss. 13, pp. 4315-4315
Open Access | Times Cited: 123
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 97
Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials
Omar S. Alkhezi, Abdullah A. Alahmed, Osamah M. Alfayez, et al.
Obesity Reviews (2022) Vol. 24, Iss. 3
Closed Access | Times Cited: 82
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 2, pp. 179-191
Open Access | Times Cited: 75
Obesity and diabetes
Chrysoula Boutari, Antea DeMarsilis, Christos S. Mantzoros
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110773-110773
Closed Access | Times Cited: 57
Adverse Events Related to Tirzepatide
Rahul Mishra, Rishi Raj, Ghada Elshimy, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 51
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes
Yoshitaka Hashimoto, Fuyuko Takahashi, Takuro Okamura, et al.
Metabolism (2023) Vol. 144, pp. 155585-155585
Closed Access | Times Cited: 45
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1206-1222
Open Access | Times Cited: 30
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Min‐Hsiang Chuang, Jui‐Yi Chen, Hsien‐Yi Wang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2427258-e2427258
Open Access | Times Cited: 23
Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan, B.C. Tan, Yip Han Chin, et al.
Obesity (2024) Vol. 32, Iss. 5, pp. 840-856
Closed Access | Times Cited: 20
Tirzepatide: A Review in Type 2 Diabetes
Nicole L. France, Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 2, pp. 227-238
Closed Access | Times Cited: 17
Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
Aurélie Mailhac, Lars C. Pedersen, Anton Pottegård, et al.
Clinical Epidemiology (2024) Vol. Volume 16, pp. 307-318
Open Access | Times Cited: 17
Revised definition of obesity in Asian Indians living in India
Anoop Misra, Naval K. Vikram, Amerta Ghosh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025), pp. 102989-102989
Closed Access | Times Cited: 5
Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations
Muhammad Usman Shah, Alun Roebuck, Bala Srinivasan, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access | Times Cited: 4
Tirzepatide: A Systematic Update
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14631-14631
Open Access | Times Cited: 48
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 45
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Bryan C. Tan, Xin‐Hui Pan, Han Shi Jocelyn Chew, et al.
International Journal of Obesity (2023) Vol. 47, Iss. 8, pp. 677-685
Closed Access | Times Cited: 38
Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
André Scheen
Annales d Endocrinologie (2023) Vol. 84, Iss. 2, pp. 316-321
Closed Access | Times Cited: 34
The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
Merlin C. Thomas, Melinda T. Coughlan, Mark E. Cooper
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 253-273
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top